Drugs / VL-PX10
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06072794 | Oct 2023 → Oct 2025 | primary ovarian failure | Vitti Labs, LLC | Suspended | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05387239 | Nov 2022 → Nov 2024 | COVID-19, pulmonary fibrosis | Vitti Labs, LLC | Suspended | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VL-PX10 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06072794 ↗ |
| Modality | Other / unclassified | “VL-PX10 is a decellularized product consisting of proteins, lipids, and nucleic acids derived from human placenta mesenchymal stem cells.” NCT06072794 ↗ |
| Route | Intravenous | “intravenous infusion of VL-PX10 and VL-P22” NCT05387239 ↗ |